<PAGE>
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  FORM 10-KSB/A
                                 SECOND AMENDED

                 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                    FOR THE FISCAL YEAR ENDED APRIL 30, 2005

                                       Or

                 [_] TRANSITION REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


                        Commission File Number 000-50281

                         LARREA BIOSCIENCES CORPORATION
           (Name of small business issuer as specified in its charter)

             NEVADA                                           680507505
(State or other jurisdiction of                            (I.R.S. Employer
 incorporation or organization)                          Identification Number)

                            C/O PETER P. SMETEK, JR.

                         4119 Montrose Blvd., Suite 230
                              Houston, Texas 77006

                               Phone: 832-695-0096

         SECURITIES REGISTERED UNDER SECTION 12(b) OF THE EXCHANGE ACT:
                                     (None)

         SECURITIES REGISTERED UNDER SECTION 12(g) OF THE EXCHANGE ACT:

                         COMMON STOCK, $.0001 PAR VALUE
                                (TITLE OF CLASS)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [_]

Check whether the issuer is not required to file reports pursuant to Section 13
or 15(d) of the Exchange Act. [ ]

Check if disclosure of delinquent filers in response to Item 405 of Regulation
S-B, is not contained in this form and no disclosure will be continued, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
the Form 10-KSB. [_]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act). Yes [ ] No [X]

Registrant had $ 545,796 in revenues for the most recent fiscal year.

As of July 5, 2005, Registrant had 22,727,167 shares of its $.0001 par value
Common Stock issued and outstanding with an aggregate market value of the common
stock held by non-affiliates of approximately $ 1,184,025. This calculation is
based upon the closing sales price of $0.17 per share on July 5, 2005.

State issuer's revenues for its most recent fiscal year. ____________________

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates computed by reference to the price at which the common equity
was sold, or the average bid and asked price of such common equity, as of a
specified date within the past 60 days. (see definition of affiliate in Rule
12b-2 of the Exchange Act.) _______________________



                       DOCUMENTS INCORPORATED BY REFERENCE
                                     (None)

Transitional Small Business Disclosure Format (Check one): Yes |_|; No |X|


<PAGE>


                                EXPLANATORY NOTE

Because of a clerical error, this amendment to form 10-KSB/A is being filed to
replace exhibits F-1, pages 19 and 19a (Reports of Independent Registered Public
Accounting Firms) in their entirety with the following audit letters.



<PAGE>



To the Stockholders of:
Larrea Biosciences Corporation (formerly Sonic Media Corp.)

We have audited the balance sheet of Larrea Biosciences Corporation (a
development stage company) as at April 30, 2004 and the statements of
operations, stockholders' equity and cash flows for the year then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit. The financial statements as of April 30, 2003 and for the year then
ended were audited by other auditors whose report dated June 20, 2003, expressed
an unqualified opinion on these statements. The cumulative statements of
operations, stockholders' equity and cash flows for the period from May 1, 2002
(inception) to April 30, 2003 include amounts for the period from May 1, 2002
(inception) to April 30, 2003, which were audited by other auditors whose
reports have been furnished to us, and in our opinion, insofar as it relates to
the amounts included for the period May 1, 2002 through April 30, 2003 is based
solely on the reports of other auditors.

We conducted our audit in accordance with Standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform an audit to obtain reasonable assurance whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.

In our opinion, based on our audits and the report of other auditors, these
financial statements present fairly, in all material respects, the financial
position of the Company as at April 30, 2004 and the results of its operations
and cash flows for the year then ended and cumulative for the period from May 1,
2002 (inception) to April 30, 2004 in conformity with accounting principles
generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 1 to the
financial statements, the Company has suffered recurring losses from operations
and negative cash flows from operations that raise substantial doubt about its
ability to continue as a going concern. Management's plans in regard to these
matters are also described in Note 1. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.

/s/ LDMB Advisors Inc.

Chartered Accountants
Langley, British Columbia, Canada
August 6, 2004


<PAGE>


             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


The Board of Directors and Stockholders
Larrea Bioscience Corporation:

We have audited the accompanying balance sheet of Larrea Bioscience Corporation
as of April 30, 2005, and related statements of operations, stockholders'
equity, and cash flows for the year ended April 30, 2005. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.

We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Larrea Bioscience Corporation
as of April 30, 2005, and the results of its operations and its cash flows for
the year ended April 30, 2005, in conformity with accounting principles
generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 9 to the
financial statements, the Company has limited capital. The Company's future
operations are dependent upon its ability to obtain third party equity and/or
debt financing and ultimately have future profitable operations. These factors
raise substantial doubt about the Company's ability to continue as a going
concern... The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

The consolidated financial statements for the year ended April 30, 2005 have
been restated (see note 11).


/s/ R. E. Bassie & Co.


Houston, Texas
March 17, 2006


<PAGE>



                                   SIGNATURES

In accordance with Section 13 or 15 (d) of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                         LARREA BIOSCIENCES CORPORATION




Date: May 17, 2006                                BY: /S/ PETER P. SMETEK, JR.
                                                     ---------------------------
                                                     Peter P. Smetek, Jr. CEO


Date: May 17, 2006                                BY: /S/ GARY D. WOERZ
                                                     ---------------------------
                                                     Gary D. Woerz, CFO




In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on the
dates indicated.




Date: May 17, 2006                                 BY: /S/ PETER P. SMETEK, JR.
                                                      --------------------------
                                                      Peter P. Smetek, Jr.,
                                                      CEO, Director


Date: May 17, 2006                                 BY: /S/ GARY D. WOERZ
                                                      --------------------------
                                                      Gary D. Woerz, CFO